Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Most antidepressants take weeks to produce meaningful relief. For the roughly one-third of patients with depression who don't respond to standard medications at all, that wait can feel endless. In 2006, a small but groundbreaking trial demonstrated that a single intravenous dose of ketamine could reduce depressive symptoms within hours — a finding that fundamentally shifted how researchers think about treating depression.
The study that opened this door was led by Carlos Zarate Jr. and colleagues at the National Institute of Mental Health. Published in Archives of General Psychiatry in 2006, the trial used a randomized, placebo-controlled, double-blind crossover design — the gold standard for clinical evidence. Eighteen patients with treatment-resistant major depression received either a single intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) or saline placebo, with each patient eventually receiving both treatments separated by at least one week.
The results were striking. Within two hours of ketamine infusion, subjects showed significant improvement in depressive symptoms compared to placebo. By 24 hours, 71% of patients met criteria for clinical response, and 29% achieved full remission. The effect size was large, and the speed of onset was unlike anything previously documented for a pharmacological intervention in depression. Improvement was still detectable at one week in some participants, though symptoms tended to return over time without additional treatment.
The mechanism behind this rapid action centers on ketamine's role as an NMDA (N-methyl-D-aspartate) receptor antagonist. By blocking NMDA receptors, ketamine is thought to trigger a downstream surge in glutamate — the brain's primary excitatory neurotransmitter. This glutamate surge activates AMPA receptors, which in turn stimulate signaling pathways involved in synaptic plasticity and the release of brain-derived neurotrophic factor (BDNF). In essence, ketamine may help the brain rapidly form new neural connections that have been impaired by chronic depression — a process that traditional antidepressants achieve far more slowly, if at all.
From a physician's perspective, the Zarate trial was a paradigm shift. For decades, the monoamine hypothesis — the idea that depression stems primarily from deficits in serotonin, norepinephrine, or dopamine — dominated drug development. Every major class of antidepressant targets monoamine systems. Ketamine's mechanism is fundamentally different. It acts on the glutamate system, suggesting that depression involves disruptions in neural circuitry and plasticity that monoamine-focused drugs may not adequately address.
This doesn't mean traditional antidepressants are ineffective — they help many patients. But ketamine's rapid onset has profound implications for acute situations, including severe depressive episodes and periods of crisis. It also opened the floodgates for an entirely new category of research into glutamatergic treatments for mood disorders.
If you've tried multiple antidepressants without adequate relief, the biology behind your experience may involve pathways that those medications simply don't target well. Ketamine works through a different mechanism, and the clinical evidence suggests it may provide rapid symptom improvement where other approaches have stalled.
It is important to note that ketamine is not FDA-approved for the treatment of depression (the FDA-approved nasal spray esketamine, marketed as Spravato, is a related but distinct product). However, ketamine is legally prescribed off-label by physicians for mood disorders, and at-home sublingual ketamine therapy has made this treatment more accessible for patients who may not be near an infusion clinic.
Ketamine's rapid antidepressant effects appear to stem from its action on the NMDA receptor and downstream glutamate signaling — a fundamentally different pathway from traditional antidepressants. The 2006 Zarate trial provided the first rigorous clinical evidence for this effect, and it remains one of the most cited studies in modern psychiatry.
Reference: Zarate CA Jr, Singh JB, Carlson PJ, et al. "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant depression." Archives of General Psychiatry. 2006;63(8):856-864. PMID: 16894061
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
